How many institutions held STRO - SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share in Q1 2026?

2 institutional investors reported STRO - SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share for Q1 2026. Use the holders table for investor-level position and value details.

SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO)

Q: What does CUSIP 869367102 represent in this 13F holders report?

CUSIP 869367102 is the security identifier for STRO - SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

CUSIP: 869367102

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 16,611,035
Total 13F shares: 106
Share change: 0
Total reported value: $2,641
Price per share: $24.92
Number of holders: 2

Quarterly Holders Quick Answers

What is CUSIP 869367102?
CUSIP 869367102 identifies STRO - SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 869367102:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of STRO - SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
BIOTECHNOLOGY VALUE FUND L P	13D/G	BVF PARTNERS L P/IL	7.6%	1,251,788	$13,306,506	$0	10 Feb 2026	13D/G
Affinity Asset Advisors, LLC	13F 13D/G	Company	8.8% from 13D/G	748,382	$8,658,780	—	31 Dec 2025	13F 13D/G
Kynam Capital Management, LP	13F 13D/G	Company	6.4% from 13D/G	479,590	$5,548,856	—	31 Dec 2025	13F 13D/G
MILLENNIUM MANAGEMENT LLC	13D/G 13F	Company	1.3%	210,378	$5,240,663	-$112,268,464	31 Mar 2026	13D/G 13F
VANGUARD GROUP INC	13F 13D/G	Company · The Vanguard Group	4.9% from 13D/G	375,786	$4,347,844	—	31 Dec 2025	13F 13D/G
ACADIAN ASSET MANAGEMENT LLC	13F	Company	2.1%	337,953	$3,908,000	—	31 Dec 2025	13F
Velan Capital Investment Management LP	13F	Company	1.9%	312,000	$3,609,840	—	31 Dec 2025	13F
Merck & Co., Inc.	13F	Company	1.6%	272,351	$3,151,101	—	31 Dec 2025	13F
Vestal Point Capital, LP	13F	Company	1.5%	243,000	$2,811,510	—	31 Dec 2025	13F
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	1.4%	230,049	$2,661,667	—	31 Dec 2025	13F
Samsara BioCapital, LLC	13F	Company	1.2%	204,503	$2,366,100	—	31 Dec 2025	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	1.2%	200,000	$2,314,000	—	31 Dec 2025	13F
Eversept Partners, LP	13F	Company	1.2%	193,571	$2,239,616	—	31 Dec 2025	13F
Opaleye Management Inc.	13F	Company	1.2%	190,671	$2,206,063	—	31 Dec 2025	13F
Point72 Asset Management, L.P.	13F	Company	1.1%	179,088	$2,072,048	—	31 Dec 2025	13F
TANG CAPITAL MANAGEMENT LLC	13F	Company	0.85%	139,617	$1,615,369	—	31 Dec 2025	13F
BlackRock, Inc.	13D/G 13F	Company	2.5%	2,092,281	$1,493,679	-$2,892,242	30 Jun 2025	13D/G 13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.75%	122,865	$1,421,548	—	31 Dec 2025	13F
William J. Newell	3/4/5	CEO, Director	— mixed-class rows	768,806 mixed-class rows	$1,399,621	—	05 Mar 2025	3/4/5
GSA CAPITAL PARTNERS LLP	13F	Company	0.54%	89,067	$1,031,000	—	31 Dec 2025	13F
MARSHALL WACE, LLP	13F	Company	0.52%	85,615	$990,565	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.51%	83,979	$971,990	—	31 Dec 2025	13F
Spruce Street Capital LP	13F	Company	0.46%	75,594	$874,623	—	31 Dec 2025	13F
ACUTA CAPITAL PARTNERS, LLC	13F	Company	0.41%	67,451	$780,408	—	31 Dec 2025	13F
ADAR1 Capital Management, LLC	13F	Company	0.41%	67,077	$776,081	—	31 Dec 2025	13F
Jane Chung	3/4/5	Chief Executive Officer, Director	— mixed-class rows	201,285 mixed-class rows	$755,524	+$10,011	04 Mar 2026	3/4/5
TWO SIGMA INVESTMENTS, LP	13F	Company	0.28%	46,492	$537,912	—	31 Dec 2025	13F
Trevor Hallam	3/4/5	Pres. Rsrch & Cf. Sctific Ofcr	— mixed-class rows	107,868 mixed-class rows	$507,563	—	14 Apr 2023	3/4/5
Fisher Asset Management, LLC	13F	Company	0.21%	35,305	$408,478	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	0.21%	34,266	$396,458	—	31 Dec 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.19%	32,085	$371,223	—	31 Dec 2025	13F
Arturo Molina MD	3/4/5	Chief Medical Officer	— mixed-class rows	127,236 mixed-class rows	$354,016	—	04 Mar 2022	3/4/5
Hans-Peter Gerber	3/4/5	CHIEF SCIENTIFIC OFFICER	— mixed-class rows	54,518 mixed-class rows	$350,294	+$13,607	01 Mar 2026	3/4/5
Shay Capital LLC	13F	Company	0.15%	24,255	$280,630	—	31 Dec 2025	13F
David Pauling	3/4/5	Chief Admin. Ofcr. & GC	— mixed-class rows	43,348 mixed-class rows	$275,374	+$9,993	04 Mar 2026	3/4/5
Shabbir Anik	3/4/5	Chief Technical Ops. Officer	— mixed-class rows	58,327 mixed-class rows	$274,452	—	03 Mar 2023	3/4/5
JANE STREET GROUP, LLC	13F	Company	0.14%	22,945	$265,473	—	31 Dec 2025	13F
Venkatesh Srinivasan	3/4/5	CHIEF TECH OP OFFICER	— mixed-class rows	254,436 mixed-class rows	$214,524	—	01 May 2025	3/4/5
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.11%	18,034	$208,654	—	31 Dec 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.11%	17,580	$203,401	—	31 Dec 2025	13F
AJU IB Investment Co., Ltd.	13F	Company	0.11%	17,500	$202,475	—	31 Dec 2025	13F
Invesco Ltd.	13F	Company	0.1%	16,970	$196,343	—	31 Dec 2025	13F
Anne Elizabeth Borgman	3/4/5	CHIEF MEDICAL OFFICER	— mixed-class rows	115,264 mixed-class rows	$195,061	—	01 May 2025	3/4/5
MORGAN STANLEY	13F	Company	0.1%	15,922	$184,218	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.1%	15,669	$181,290	—	31 Dec 2025	13F
RBF Capital, LLC	13F	Company	0.09%	15,272	$176,697	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.09%	14,379	$166,365	—	31 Dec 2025	13F
Edward C. Albini	3/4/5	CFO AND SECRETARY	0.97%	160,805	$141,508	—	15 May 2025	3/4/5
Linda A. Fitzpatrick	3/4/5	CHIEF PEOPLE & COMM. OFFICER	— mixed-class rows	136,658 mixed-class rows	$134,667	—	01 May 2025	3/4/5
OMERS ADMINISTRATION Corp	13F	Company	0.07%	11,023	$127,536	—	31 Dec 2025	13F

Institutional Holders of SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO) as of Q1 2026

As of 31 Mar 2026, SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO) was held by 2 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 106 shares. The largest 2 holders included Fortitude Family Office, LLC and Bogart Wealth, LLC. This page lists 2 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

Q1 2026 holders

Holder diff

-4

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.